Venous thromboembolism in cancer patients: An underestimated major health problem

World Journal of Surgical Oncology

Volumn 13, Issue 1, 2015, Pages

  Khalil, Jihane ^a   Bensaid, Badr ^b   Elkacemi, Hanan ^a   Afif, Mohamed ^a   Bensaid, Younes ^b   Kebdani, Tayeb ^a   Benjaafar, Noureddine ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

Author keywords

Anticoagulation; Cancer; Thromboprophylaxis; Venous thromboembolism

Indexed keywords

ANTIVITAMIN K; APIXABAN; CANCER PROCOAGULANT; DABIGATRAN; FONDAPARINUX; HEPARIN; IMMUNOMODULATING AGENT; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RIVAROXABAN; THROMBOPLASTIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER LOCALIZATION; CANCER PATIENT; CANCER SCREENING; CATHETER THROMBOSIS; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL (TOPIC); COMPRESSION STOCKING; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; KIDNEY FAILURE; LONG TERM CARE; LOWER EXTREMITY DEEP VEIN THROMBOSIS; LUNG EMBOLISM; MAINTENANCE THERAPY; META ANALYSIS (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL PATIENT; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; THROMBOSIS PREVENTION; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; COMPLICATION; NEOPLASM; PROGNOSIS;

HUMANS; NEOPLASMS; PROGNOSIS; VENOUS THROMBOEMBOLISM;

EID: 84934290027     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/s12957-015-0592-8     Document Type: Review

References (154)

1. Khorana AA, Francis CW, Culakova E, Kuderer N, Lyman H, et al. Thromboembolism in hospitalized cancer patients. J Clin Oncol. 2006;24:484-90.
2. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002;87:575-9.
3. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon W, Melton 3rd LJ, et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population based case-control study. Arch Intern Med. 2000;160:809-15.
4. Chew HK, Wun T, Harvey DJ, Zhou H, White RH, et al. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166:458-64.
5. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343:1846-50.
6. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5:632-4.
7. Trousseau A. Plegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris. 1865;5:281-332.
8. Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;31:2189-204.
9. NCCN Guidelines Venous Thromboembolic Disease. Version 2.2014
10. A. Falanga, F. Roila. On behalf of the ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.
11. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. National Institute For Health And Clinical Excellence. Clinical guideline.
12. Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11:56-70.
13. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians. Evidence-Based Clinical Practice Guidelines.
14. Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N et al. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS). 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
15. Lyman GH, Khorana AA. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009;27:4821-6.
16. Amin A, Spyropoulos AC, Dobesh P, Shorr A, Hussein M, Mozaffari E, et al. Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start). J Thromb Thrombolysis. 2010;29:326-39.
17. Kucher N, Spirk D, Baumgartner I, Mazzolai L, Korte W, Nobel D, et al. Lack of prophylaxis before the onset of acute venous thromboembolism among hospitalized cancer patients: the SWIss Venous Thrombo Embolism Registry (SWIVTER). Ann Oncol. 2010;21:931-5.
18. Khorana AA. Cancer and coagulation. Am J Hematol. 2012;87(SV):S82-7.
19. Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15(22):6830-40.
20. Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry. 1985;24(20):5558-67.
21. Donati MB, Gambacorti-Paserini C, Casali B, Falanga A, Vanoti P, Fosati G, et al. Cancer procoagulant in human tumor cells: evidence from melanoma patients. Cancer Res. 1986;46(12 Pt 1):6471-4.
22. Mielicki W, Serwa J, Kurzawinski T, Wierzbicki R. Procoagulant activity of human stomach and colon cancers. Oncology. 1990;47(4):299-302.
23. Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Pract Res Clin Haematol. 2009;22(1):49-60.
24. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9:237-49.
25. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005;105(1):178-85.
26. Nierodzik ML, Klepfish A, Karpatkin S. Role of platelets, thrombin, integrin IIb-IIIa, fibronectin and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost. 1995;74:282-90.
27. Brasky TM, Baik CS, Slatore CG, Alvarado M, Emily. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg. 2010;38:21-6.
28. Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow C, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet. 2010;376:1741-50.
29. J A. Heit, MD. Silverstein, DN. Mohr, TM. Petterson, MO'Fallon, LJ Melton III. Thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000.
30. Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and metaanalysis. J Clin Oncol. 2012;30:4416-26.
31. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5- fluorouracil alone or in combination with cisplatin. Cancer. 1990;65:885-9.
32. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, Warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986-93.
33. Santos AB, Llamas P, Román A, Prieto E, De Ona R, De Velasco JF, et al. Evaluation of thrombophilic states in myeloma patients receiving thalidomide: a reasonable doubt. Br J Haematol. 2003;122:159-67.
34. Swystun LL, Mukherjee S, Liaw PC. Breast cancer chemotherapy induces the release of cell-free DNA, a novel procoagulant stimulus. J Thromb Haemost. 2011;9:2313-21.
35. Demers M, Krause DS, Schatzberg D, Martinod K, Voorhees JR, Fuchs TA, et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Nat Acad Sci USA. 2012;109:13076-81.
36. Lechner D, Weltermann A. Pathophysiologie derchemotherapie-assoziierten thrombose. Hämostaseologie. 2008;28:112-20.
37. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res. 2006;118:555-68.
38. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-93.
39. Khorana A, Dalal M, Lin J, Connolly GC. Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients in the United States. Cancer. 2013;119:648-55.
40. Falanga A, Marchetti M. Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27:4848-57.
41. Cavo M, Zamagni E, Cellini C, Tosi P, Cangini D, Cini M, et al. Deep-vein thrombosis inpatients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002;100:2272-3.
42. Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293:715-22.
43. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
44. Khorana AA, Herman K, Rubens D, Francis CW. A predictive risk score for cancer associated thrombosis: role of screening in a prospective study. Blood (ASH Annual Meeting Abstracts); 2010.119:abstr.3173.
45. George D, Agnelli G, Fisher W, Kakkar A, Lassen MR, Mismetti P et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO. Blood (ASH Annual Meeting Abstracts) 2011;118: abstr.206.
46. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol. 2011;29:3466-73.
47. Mandala M, Clerici M, Corradino I, Vitalini C, Colombini S, Torri V, et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated with in the context of phase I studies: the 'SENDO experience'. Ann Oncol. 2012;23:1416-21.
48. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902-7.
49. Agnelli G, Verso M, Ageno W, Imberti D, Moia M, Palareti G, et al. The MASTER registry on venous thromboembolism: description of the study cohort. Thromb Res. 2008;121:605-10.
50. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med. 2006;144:812-21.
51. Strouse JJ, Tamma P, Kickler TS, Takemoto CM. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med. 2003;349:1227-35.
52. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood. 2000;96:2364-8.
53. Sohne M, Kruip MJHA, Nijkeuter M, Tick L, Kwakkel H, Halkes SJM, et al. Accuracy of clinical decision rule, D-dimer and spiral computed tomography in patients with malignancy, previous venous thromboembolism, COPD or heart failure and in older patients with suspected pulmonary embolism. J Thromb Haemost. 2006;4:1042-6.
54. Knowlson L, Bacchu S, Paneesha S, McManus A, Randall K, Rose P, et al. Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism. J Clin Pathol. 2010;63:818-22.
55. Zierler BK, Stevens SM, Elliott CG, Chan KJ, Egger MJ, Ahmed KM, et al. Ultrasonography and diagnosis of venous thromboembolism. Circulation. 2004;109:I9-14.
56. Birdwell BG, Raskob GE, Whitsett TL, Durica SS, Comp PC, George JN, et al. The clinical validity of normal compression ultrasonography in outpatients suspected of having deep venous thrombosis. Ann Intern Med. 1998;128:1-7.
57. Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation. 2004;109:15-21.
58. Gaitini D. Current approaches and controversial issues in the diagnosis of deep vein thrombosis via duplex Doppler ultrasound. J Clin Ultrasound. 2006;34:289-97.
59. Fraser DGW, Moody AR, Davidson IR, Martel AL, Morgan PS. Deep venous thrombosis: diagnosis by using venous enhanced subtracted peak arterial MR venography versus conventional venography. Radiology. 2003;226:812-20.
60. Sampson FC, Goodacre SW, Thomas SM, van Beek EJ. The accuracy of MRI in diagnosis of suspected deep vein thrombosis: systematic review and meta-analysis. Eur Radiol. 2007;17:175-81.
61. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler M, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis. 1986;16:159-64.
62. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
63. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9.
64. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. BMJ. 2006;332:325-9.
65. Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. AnnSurg. 1988;208:227-40.
66. Shukla PJ, Siddachari R, Ahire S, Arya S, Ramani S, Barreto SG, et al. Postoperative deep vein thrombosis in patients with colorectal cancer. Ind J Gastroenterol. 2008;27:71-3.
67. Mismetti P, Laporte S, Darmon JY, Buchmüller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg. 2001;88:913-30.
68. Einstein MH, Pritts EA, Hartenbach EM. Venous thromboembolism prevention in gynecologic cancer surgery: a systematic review. Gynecol Oncol. 2007;105:813-9.
69. Oates-Whitehead R, D_Angelo A, Mol B. Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. Cochrane Database Syst Rev. 2003;4, CD003679.
70. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg. 1997;84:1099-103.
71. Baykal C, Al A, Demirtaş E, Ayhan A. Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomized prospective double-blind clinical study. Eur J Gynaecol Oncol. 2001;22:127-30.
72. McLeod RS, Geerts WH, Sniderman KW, Greenwood C, Gregoire RC, Taylor BM, et al. Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery. Ann Surg. 2001;233:438-44.
73. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, et al. Low molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med. 2008;168:1261-9.
74. Bergqvist D, Burmark US, Flordal PA, Frisell J, Hallböök T, Hedberg M, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 vs 5000 Xa IU in 2070 patients. Br J Surg. 1995;82:496-501.
75. Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med. 2002;346:975-80.
76. Lausen I, Jensen R, Jorgensen LN, Rasmussen MS, Lyng KM, Andersen M, et al. Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxis. Eur J Surg. 1998;164:657-63.
77. Melon E, Keravel Y, Gaston A, Huet Y, Combes S, the NEURONOX Group. Deep venous thrombosis prophylaxis by LMWH in neurosurgical patients. Anesthesiology. 1991;75:A214.
78. Nurmohamed MT, van Riel AM, Henkens CM, Koopman MM, Que GT, d_Azemar P, Büller HR, ten Cate JW, Hoek JA, van der Meer J, van der Heul C, Turpie AG, Haley S, Sicurella A, Gent M. Low molecular weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemost 1996; 75: 233-8.
79. Di Nisio M, Porreca E, Ferrante N, Otten HM, Cuccurullo F, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 2012 Feb;15 (2) (CD008500)
80. Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, et al. PROTECHT investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double blind study.LancetOncol2009;10:943-949.
81. Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, et al. Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer. Clin Appl Thromb Hemost. 2012;18:159-65.
82. Perry JR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogers LR, et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost. 2010;8:1959-65.
83. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide associated thrombosis in myeloma. Leukemia. 2008;22:414-23.
84. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101:762-9.
85. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, et al. Long-term low-molecular-weight heparin versus usual care in proximal vein thrombosis patients with cancer. Am J Med. 2006;119:1062-72.
86. Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low molecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-53.
87. Romera A, Cairols MA, Vila-Coll R, Martí X, Colomé E, Bonell A, et al. A randomised open label trial comparing long-term subcutaneous low-molecular-weight heparin compared with oral anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg. 2009;37:349-56.
88. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: metaanalysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1:1906-13.
89. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandalá M, Papaldo P, Fabi A, Ciccarese M, Cuppone F, Cecere FL, Nuzzo C, Terzoli E, Cognetti F. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants? Chest 2006; 130: 1808-16.
90. Louzada M, Majeed H, Wells P. Efficacy of low-molecular-weight heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009;123:837-44.
91. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2008;2, CD006650.
92. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, et al. Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 2008;27:21.
93. Noble SI, Shelley MD, Coles B, Williams SM, Wilcock A, Johnson MJ, et al. Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:577-84.
94. Cohen J, Tenenbaum N, Citron M. Greenfield filter as primary therapy for deep venous thrombosis and/or pulmonary embolism in patients with cancer. Surgery. 1991;109:12-5.
95. Cohen J, Grella L, Citron M. Greenfield filter instead of heparin as primary treatment for deep venous thrombosis or pulmonary embolism in patients with cancer. Cancer. 1992;70:1993-6.
96. Olin JW, Young JR, Graor RA, Ruschhaupt WF, Beven EG, Bay JW. Treatment of deep vein thrombosis and pulmonary emboli in patients with primary and metastatic brain tumors. Anticoagulants or inferior vena cava filter? Arch Intern Med 1987; 147:2177-9
97. Hubbard K, Roehm J, Abbruzzese JL. The Bird's Nest Filter. An alternative to long-term oral anticoagulation in patients with advanced malignancies. Am J Clin Oncol. 1994;17:115-7.
98. Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1996;14:652-7.
99. Greenfield L, Proctor M, Saluja A. Clinical results of Greenfield filter use in patients with cancer. Cardiovasc Surg. 1997;5:145-9.
100. Schleich JM, Morla O, Laurent M, Langella B, Chaperon J, Almange C. Long-term follow-up of percutaneous vena cava filters: a prospective study in 100 consecutive patients. Eur J Vasc Endovasc Surg. 2001;21:450-7.
101. Jarrett BP, Dougherty MJ, Calligaro KD. Inferior vena cava filters in malignant disease. J Vasc Surg. 2002;36:704-7.
102. Wallace MJ, Jean JL, Gupta S, Eapen GA, Johnson MM, Ahrar K, et al. Use of inferior vena caval filters and survival in patients with malignancy. Cancer. 2004;101:1902-7.
103. Zerati AE, Wolosker N, Yazbek G, Langer M, Nishinari K. Vena cava filters in cancer patients: experience with 50 patients. Clinics (Sao Paulo, Brazil) 2005; 60: 361-6.
104. Schunn C, Schunn GB, Hobbs G, Vona-Davis LC, Waheed U. Inferior vena cava filter placement in late-stage cancer. Vasc Endovasc Surg. 2006;40:287-94.
105. Otten HM, Prins MH. Venous thromboembolism and occult malignancy. Thromb Res. 2001;102:V187-94.
106. Piccioli A, Prandoni P. Venous thromboembolism as first manifestation of cancer. Acta Haematol. 2001;106:13-7.
107. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet. 1998;351:1077-80.
108. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323-33.
109. Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83:180-5.
110. Murchison JT, Wylie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study. Br J Cancer. 2004;91:92-5.
111. Rieu V, Chanier S, Philippe P, Ruivard M. Systematic screening for occult cancer in elderly patients with venous thromboembolism: a prospective study. Intern Med J. 2011;41:769-75.
112. Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism duration of anticoagulation trial. N Engl J Med. 2000;342:1953-8.
113. Sørensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med. 1998;338:1169-73.
114. Piccioli A, Lensing AWA, Prins A, Falanga LS, Ieran M, Cigolini M, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb and Haemostasis. 2004;2:884-9.
115. Rondina MT, Uyen T, Pendleton Robert C, Kraiss Larry W, Robert C, McMillin Gwendolyn A, et al. A pilot study utilizing whole body 18-FDG PET CT as a comprehensive screening strategy for occult malignancy in patient with unprovoked venous thromboembolism.
116. Van Doormal F, Terpstra W, Van Der Griend R, Prins MH, Nijziel MR, Van De Ree MA, et al. Is extensive screening in idiopathic in idiopathic venous thromboembolism warranted?
117. Palomares LJ, Eraso CC, Hernandez TE, Galvan MF, Pelaez SM, Cayuela A, et al. Testing for occult cancer in patients with pulmonary embolism.
118. Maher EA, McKee AC. Neoplasms of the central nervous system. In: Skarin AT, Canellos GP, editors. Atlas of diagnostic oncology (ed 3rd). London, United Kingdom: Elsevier Science Ltd; 2003.
119. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005;75:5-14
120. Levin JM, Schiff D, Loeffler JS, Fine HA, Black PM, Wen PY. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology. 1993;43:1111-4.
121. Schiff D, De Angelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer. 1994;73:493-8.
122. Gerber DE, Grossman SA, Streiffand MB, et al. Management of venous thromboembolism in patients with primary and metastatic brain metastases. JCO. 2006;24:8.
123. Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost. 1996;75:251-3.
124. Heaton DC, Han DY, Inder A. Minidose (1 mg) warfarin as prophylaxis for central vein catheter thrombosis. Intern Med J. 2002;32:84-8.
125. Couban S, Goodyear M, Burnell MSD, Wasi P, Barnes D, MacLeod D, et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23:4063-9.
126. Karthaus M, Kretzschmar A, Kroning H, Biakhov M, Irwin D, Marschner N, et al. Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Ann Oncol. 2006;17:289-96.
127. Verso M, Agnelli G, Bertoglio S, et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo controlled, randomized study in cancer patients. J Clin Oncol. 2005;23:4057-62.
128. Iversen LH, Thorlacius-Ussing O. Systemic coagulation reactivation in recurrence of colorectal cancer. J Thromb Haemost. 2003;89:726-34.
129. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer TH, et al. Coagulation markers predict survival in cancer patients. J Thromb Haemost. 2002;88:745-9.
130. Erpenbeck L, Schön M. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010;115:3427-36.
131. Gasic GJ, Gasic TB, Murophy S. Anti-metastatic effect of aspirin. Lancet. 1972;2(7783):932-3.
132. Ornstein LD, Zacharski LR. The use of heparin for treating human malignancies. Haemostasis. 1999;29(Suppl1):48-60.
133. Smorenburg SM, van Noorden CJF. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev. 2001;53:93-105.
134. Astedt B, Glifberg I, Mattsson W, Trope C. Arrest of growth of ovarian tumor by tranexamic acid. JAMA. 1977;238:154-155.
135. Astedt B, Mattsson W, Trope C. Treatment of advanced breast cancer with chemotherapeutics and inhibition of coagulation and fibrinolysis. Acta Med Scand. 1977;201:491-3.
136. Sadoff L, Latino F. Complete clinical remission in a patient with advanced pancreatic cancer using Mitomycin C-based chemotherapy: the role of adjunctive heparin. Am J Clin Oncol. 1999;22:187-90.
137. Loynes JT. Regression of metastatic non-small cell lung cancer with low molecular weight heparin. J Thromb Haemost. 2002;88:686.
138. Elias EG, Shukia SK, Mink IB. Heparin and chemotherapy in the management of inoperable lung carcinoma.Cancer. 1975;36:129-136.
139. Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delasements C, et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. Cancer. 1994;7:38-45.
140. Altinbas M, Coskun HS, Er O, Ozkan M, Eser B, Unal A, et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2004;2:1266-71.
141. Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low molecular-weight versus standard heparin.
142. Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR. On behalf of the fragmin advanced malignancy outcome study (FAMOUS) investigators. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004;22:1944-1948.
143. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23:2130-5.
144. Riess H, Pelzer U, Deutschinoff G. PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy. ASCO 2009, abstract LBA4506
145. Sideras K, Schaefer PL, Okuno SH, Sloan JA, Kutteh L, Fitch TR, et al. Low- molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc. 2006;81:758-67.
146. Weber C, Merminod T, Herrmann FR, Zulian GB. Prophylactic anti-coagulation in cancer palliative care: a prospective randomized study. Support Care Cancer. 2008;16:847-52.
147. van Doormaal FF, Di Nisio M, Otten HM, Richel DJ, Prins M, Buller HR. Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol. 2011;29:2071-6.
148. Akl EA, Gunukula S, Barba M, Yosuico VED, van Doormaal FF, Kuipers S, et al. Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane review.
149. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119(13):3016-23.
150. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510.
151. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699-708.
152. Levine MN, Gu C, Liebman HA, Escalante CP, Solymoss S, Deitchman D, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10(5):807-14.
153. Cohen AT, Spiro TE, Buller HR, Haskell L, Hu D., Hull R, et al. Rivaroxaban vs. enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients: Magellan subgroup analyses. J Thromb Haemost (ISTH annual meeting abstracts) 2011;9(Suppl. 2):21, abstr. O-MO-034.
154. Büller HR. On behalf of the EINSTEIN investigators. Oral rivaroxaban for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Blood (ASH annual meeting abstracts) 2012.